• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BLU alert in real time by email

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors.

    "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through several key value inflection points in the coming years. We look forward to their contributions to our company's success."

    Mr. Forrester has more than 25 years of life sciences experience and has held leadership roles in private and public pharmaceutical companies. He is a co-founder of IDRx, EQRx, Brixton Biosciences and EyeCool Therapeutics and has served as the CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He also serves on the boards of AffyImmune Therapeutics, Pillar Biosciences and Deciduous Therapeutics. Robert also served as Managing Director of the Proprietary Investment Group at MeesPierson and worked as an investment banker at Barclays and UBS. Mr. Forrester holds an LL.B. from Bristol University, UK.

    "I am truly excited to join the OnCusp Board at this transformative moment for the company." Mr. Forrester stated, "I am equally enthusiastic about OnCusp's lead program, CUSP06, a thoughtfully designed second-in-class CDH6 ADC with clearly differentiated attributes. I look forward to working with other board members and the executive team to maximize the potential of the company's promising pipeline."

    Mr. Khuong was most recently General Partner and Senior Advisor at Catalio Capital Management, LP where he served on the Investment Committees of Catalio's flagship private equity strategy and its Credit Opportunities strategy. He previously spent nearly twenty years at OrbiMed Advisors, where he contributed significantly to the firm's growth into one of the premier healthcare-focused investing organizations globally.  At the time of his retirement from OrbiMed in December 2021, Chau was Partner and Member of the Investment Committee for the OrbiMed venture capital funds. He has led or co-led investments into over two dozen life science companies, ultimately resulting in twelve FDA approved medicines or therapeutic devices. Chau has served as a representative on the Board of Directors of numerous public and private biotech companies such as Bellus Health (NASDAQ:BLU), Glaukos (NYSE:GKOS), Inspire Medsystems (NYSE:INSP), Intellia (NASDAQ:NTLA), Rempex (acquired by MDCO), and ReViral Ltd (acquired by Pfizer).  Chau earned a B.S. and an M.P.H., both from Yale University.

    "It is a pleasure to be a part of OnCusp and to collaborate with such an experienced management team," said Mr. Khuong. "I am impressed with the progress that OnCusp has made since its inception last year and look forward to leveraging my financial expertise and extensive relationships to drive growth and success for the company."

    About OnCusp Therapeutics

    OnCusp Therapeutics is a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics. OnCusp was founded by a world-class team with a proven track record in building a startup biotech to the commercialization stage, leading successful global clinical programs, and creating value in mutually beneficial partnerships. OnCusp's business model is to develop preclinical assets to clinical proof of concept and then partner out for commercialization. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp is backed by prominent investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, AIHC Capital, WuXi Biologics HealthCare Venture and 3R Capital. OnCusp has its headquarters in New York City and an office in Shanghai.

    Cision View original content:https://www.prnewswire.com/news-releases/oncusp-therapeutics-announces-appointment-of-robert-forrester-and-chau-khuong-to-board-of-directors-301713160.html

    SOURCE OnCusp

    Get the next $BLU alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLU
    $GKOS
    $INSP
    $NTLA

    CompanyDatePrice TargetRatingAnalyst
    Glaukos Corporation
    $GKOS
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    Intellia Therapeutics Inc.
    $NTLA
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    Intellia Therapeutics Inc.
    $NTLA
    3/5/2025$30.00Buy
    H.C. Wainwright
    Intellia Therapeutics Inc.
    $NTLA
    2/28/2025$45.00 → $13.00Overweight → Neutral
    Analyst
    Intellia Therapeutics Inc.
    $NTLA
    2/28/2025$9.00Neutral → Sell
    Goldman
    Glaukos Corporation
    $GKOS
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    Intellia Therapeutics Inc.
    $NTLA
    1/27/2025$56.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    Glaukos Corporation
    $GKOS
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    More analyst ratings

    $BLU
    $GKOS
    $INSP
    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Technical Officer Clark Eliana sold $10,036 worth of shares (1,022 units at $9.82), decreasing direct ownership by 1% to 95,369 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      7/3/25 4:11:49 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VP, Chief Accounting Officer Dube Michael P sold $24,905 worth of shares (2,503 units at $9.95), decreasing direct ownership by 4% to 57,137 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      7/3/25 4:07:21 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Goodman Jesse sold $29,068 worth of shares (3,094 units at $9.40), decreasing direct ownership by 11% to 24,359 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      7/2/25 5:50:11 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Glaukos downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

      5/1/25 7:44:23 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Intellia Therapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00

      4/21/25 8:30:53 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • H.C. Wainwright initiated coverage on Intellia Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00

      3/5/25 7:39:47 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IDOSE TR issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/15/23 11:41:09 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • FDA Approval for TRAVOPROST issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/14/23 7:41:03 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • March 21, 2023 - FDA Roundup: March 21, 2023

      For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

      3/21/23 3:12:46 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

      Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platfor

      6/25/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

      NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 25th Equities are little changed Wednesday morning after jumping by more than 1% on Tuesday. The DOW gained over 500 points while the S&P 500 sits just shy of a record high.Driving those gains were easing tensions in the Middle East, resulting in crude oil prices falling by approximately 5% during Tuesday's session. President Trump announced a ceasefire agreement on Monday night.Fed

      6/25/25 8:55:00 AM ET
      $GKOS
      $ICE
      $JBS
      Medical/Dental Instruments
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye disease

      6/25/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      1/24/24 4:32:03 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    SEC Filings

    See more
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/16/25 7:00:17 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

      6/13/25 6:19:04 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/12/25 4:31:54 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

      4/21/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

      Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

      12/5/24 12:12:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

      Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

      11/16/24 10:16:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      11/14/24 1:21:45 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      11/12/24 10:32:14 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      10/4/24 2:09:06 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Financials

    Live finance-specific insights

    See more
    • Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

      On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z

      5/8/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug

      5/1/25 7:30:00 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care